حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Fagron NV
FAGRFagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium. Address: Venecoweg 20A, Nazareth, Belgium, 9810
Analytics
سعر الهدف في وول ستريت
20.58 EURنسبة السعر إلى الأرباح
17.9626العائد الربحي
1.67 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية FAGR
تحليلات الأرباح FAGR
نمو الأرباح على مدى 5 سنوات
150 %النمو المستمر
3 سنينمعدل الدفع 5 سنوات في المتوسط
18 %تاريخ الأرباح FAGR
تقييم الأسهم FAGR
المالية FAGR
نتائج | 2019 | ديناميات |